Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.46 |
| ▸ | F11 | P03951 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 1/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18650683 | 0.99 | PTPN1 (0.44) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL20226177 | 0.99 | PTPN1 (0.44) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL18654280 | 0.93 | PTPN1 (0.52) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL18296702 | 0.93 | PTPN1 (0.52) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL18296604 | 0.93 | PTPN1 (0.52) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL18650719 | 0.92 | PTPN1 (0.44) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL18650712 | 0.91 | PTPN1 (0.39) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL18650669 | 0.90 | LGALS9 (0.39) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL20226171 | 0.90 | LGALS9 (0.39) | PTPN1F11USP2MEN1POLB | |
| SCHEMBL17773536 | 0.89 | LGALS9 (0.42) | PTPN1F11USP2MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180154014-A1 | BETA-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES | IMMUNEXCITE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20170081428-A1 | IMMUNOMODULATING BETA-1,6-D-GLUCANS | INNATE BIOTHERAPEUTICS, LLC | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180154014-A1 | BETA-1,6-GLUCAN CETUXIMAB ANTIBODY CONJUGATES | CD47, ERBB3, FUT6 | PTPN1 708/4885F11 629/4885USP2 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.